Evidence map›Paper›PMID 40794635›Full record

Trial reportEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology2025

Personalized pulmonary vein isolation guided by left atrial wall thickness for persistent atrial fibrillation ablation: the PeAF-by-LAWT randomized trial.

Giulio Falasconi, Diego Penela, David Soto-Iglesias, Alessia Chiara Latini, Federico Landra, Emanuele Curti, Pietro Francia, Andrea Saglietto, Dario Turturiello, Daniel Viveros and 18 more

Registry-linked trialAbstract readEquivalence TrialRandomized Controlled Trial
In one paragraph

Trial report in Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05396534 (Personalized Persistent Atrial Fibrillation Ablation), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05396534 naunknown statusnot on this map

Personalized Persistent Atrial Fibrillation Ablation: The PeAF-BY-LAWT Trial

TypeinterventionalSponsorCentro Medico TeknonRan2022 to 2024Enrolled156ConditionsPersistent Atrial Fibrillation, Persistent Atrial Fibrillation LongstandingArmsAtrial Fibrillation transcatheter ablation
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Left atrial anterior wall flutter: clinical, anatomical, and electrophysiological characteristics.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2026
    Article
  2. Review
  3. Functional mapping identifies early arrhythmogenic substrate in recurrent atrial fibrillation.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2026
    Article
  4. Wall thickness-guided persistent atrial fibrillation ablation: have we found the holy grail?Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025
    Article
  5. Underexplored energy reduction, posterior dosing constraints, and bundling effects in the PeAF-by-LAWT trial.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Giulio FalasconiArrhythmia Department, Teknon Medical Center, c. Villana, 12, Barcelona 08022, Spain.ORCID 0000-0001-7128-9911
Diego PenelaArrhythmology Department, Humanitas Research Hospital IRCCS, Rozzano, Milan, Italy.ORCID 0009-0009-7221-4829
David Soto-IglesiasArrhythmia Department, Teknon Medical Center, c. Villana, 12, Barcelona 08022, Spain.ORCID 0000-0003-1394-6260
Alessia Chiara LatiniArrhythmology Department, Humanitas Research Hospital IRCCS, Rozzano, Milan, Italy.ORCID 0000-0002-6024-6278
Federico LandraArrhythmia Department, Teknon Medical Center, c. Villana, 12, Barcelona 08022, Spain.ORCID 0000-0002-2106-0884
Emanuele CurtiArrhythmia Department, Teknon Medical Center, c. Villana, 12, Barcelona 08022, Spain.
Pietro FranciaArrhythmia Department, Teknon Medical Center, c. Villana, 12, Barcelona 08022, Spain.ORCID 0000-0003-0306-7764
Andrea SagliettoArrhythmia Department, Teknon Medical Center, c. Villana, 12, Barcelona 08022, Spain.ORCID 0000-0001-9475-1507
Dario TurturielloArrhythmia Department, Teknon Medical Center, c. Villana, 12, Barcelona 08022, Spain.ORCID 0000-0001-9579-5413
Daniel ViverosArrhythmia Department, Teknon Medical Center, c. Villana, 12, Barcelona 08022, Spain.ORCID 0000-0002-8317-561X
Aldo BellidoArrhythmia Department, Teknon Medical Center, c. Villana, 12, Barcelona 08022, Spain.
Jose AldereteArrhythmia Department, Teknon Medical Center, c. Villana, 12, Barcelona 08022, Spain.ORCID 0000-0003-0318-5349
Fatima ZaraketArrhythmia Department, Teknon Medical Center, c. Villana, 12, Barcelona 08022, Spain.ORCID 0000-0002-0706-1987
Paula Franco-OcañaArrhythmia Department, Teknon Medical Center, c. Villana, 12, Barcelona 08022, Spain.ORCID 0000-0002-6157-058X
Stefano ValcherArrhythmology Department, Humanitas Research Hospital IRCCS, Rozzano, Milan, Italy.ORCID 0000-0001-8355-9894
Francesco AmataArrhythmology Department, Humanitas Research Hospital IRCCS, Rozzano, Milan, Italy.ORCID 0000-0003-3651-6765
Chiara ValerianoArrhythmology Department, Humanitas Research Hospital IRCCS, Rozzano, Milan, Italy.ORCID 0000-0002-0130-6218
Carlo GiganteArrhythmia Department, Teknon Medical Center, c. Villana, 12, Barcelona 08022, Spain.ORCID 0000-0003-2266-0344
Lucio TeresiArrhythmia Department, Teknon Medical Center, c. Villana, 12, Barcelona 08022, Spain.ORCID 0000-0001-5626-0336
Bruno TonelloArrhythmia Department, Teknon Medical Center, c. Villana, 12, Barcelona 08022, Spain.
Roberta MeaArrhythmia Department, Teknon Medical Center, c. Villana, 12, Barcelona 08022, Spain.
Lautaro Sánchez-MolláArrhythmia Department, Teknon Medical Center, c. Villana, 12, Barcelona 08022, Spain.ORCID 0009-0006-6075-7795
Carmine De LuciaArrhythmia Department, Teknon Medical Center, c. Villana, 12, Barcelona 08022, Spain.
Marina HuguetArrhythmia Department, Teknon Medical Center, c. Villana, 12, Barcelona 08022, Spain.ORCID 0000-0002-3524-6612
Óscar CámaraDepartment of Information and Communication Technologies, Pompeu Fabra University, Barcelona, Spain.ORCID 0000-0002-5125-6132
José-Tomás Ortiz-PérezArrhythmia Department, Teknon Medical Center, c. Villana, 12, Barcelona 08022, Spain.ORCID 0000-0001-8043-6055
Julio Martí-AlmorArrhythmia Department, Teknon Medical Center, c. Villana, 12, Barcelona 08022, Spain.ORCID 0000-0001-9927-1190
Antonio BerruezoArrhythmia Department, Teknon Medical Center, c. Villana, 12, Barcelona 08022, Spain.ORCID 0000-0002-5418-383X

Funding

'Ricerca Corrente' funding from Italian Ministry of Health to IRCCS Humanitas Research Hospital
6 · The paper itself

Abstract

aimsA personalized pulmonary vein isolation (PVI) approach aimed at ablation index (AI) titration according to multidetector computed tomography-derived left atrial wall thickness (LAWT) maps reported high effectiveness and efficiency outcomes for persistent atrial fibrillation (PeAF) ablation. To date, no randomized trials have compared this approach with the standard CLOSE protocol. This non-inferiority randomized controlled trial sought to compare a LAWT-guided PVI with CLOSE protocol-based for PeAF (NCT05396534). METHODS AND

resultsConsecutive patients referred for first-time PeAF ablation were randomized on a 1:1 basis. In the by-LAWT arm, the AI was titrated according to local LAWT, and the ablation line was personalized to avoid the thickest regions at the pulmonary vein antrum. In the CLOSE arm, LAWT information was not available to the operator; the ablation was performed according to the CLOSE study settings: AI is ≥400 at the posterior wall and ≥550 at the anterior wall. Primary endpoint was freedom from atrial arrhythmias recurrence. Secondary endpoints were the major complication rate, procedure time, radiofrequency time, and first-pass PVI rate. One hundred fifty-six patients were included. At 12 month follow-up, no significant difference occurred in atrial arrhythmia-free survival between groups (P = 0.50). In the by-LAWT group, a significant reduction in procedure time (60.5 vs. 80.0 min; P < 0.01) and RF time (14.4 vs. 28.6 min; P < 0.01) was observed. No difference was observed regarding first-pass PVI (P = 0.72) and the major complication rate (P = 0.99).

conclusionsThe PeAF-by-LAWT trial is the first prospective randomized study to demonstrate that a personalized LAWT-guided PVI for PeAF ablation is non-inferior to the standard CLOSE protocol in terms of arrhythmia-free survival while significantly improving procedural efficiency. The study was not powered to detect differences in safety outcomes.

Indexed as

Atrial FibrillationCatheter AblationHeart AtriaMultidetector Computed TomographyPulmonary VeinsAction PotentialsAgedFemaleHeart RateHumansMaleMiddle AgedProgression-Free SurvivalProspective StudiesRecurrenceTime FactorsCatheter ablationLeft atrial wall thicknessMultidetector computed tomographyPersistent atrial fibrillationPulmonary vein isolation

Identifiers

PMID40794635
PMCPMC12676948

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.